New AMM: Nivolumab as an adjuvant for oesophageal and gastroesophageal junction cancer

xlomafota13 shared this article with you from Inoreader New AMM: Nivolumab as an adjuvant for oesophageal and gastroesophageal junction cancer Via Association française pour l'étude du cancer Bull Cancer. 2022 Feb 11:S0007-4551(22)00009-1. doi: 10.1016/j.bulcan.2021.11.018. Online ahead of print. NO ABSTRACT PMID:35164916 | DOI:10.1016/j.bulcan.2021.11.018 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.